Endothelin biology remains an attractive therapeutic target in IgA nephropathy where intrarenal endothelin-1 expression is upregulated and implicated in nephron loss through vasoconstriction, ...

A growing body of epidemiological evidence points to an inverse relationship between cancer and Alzheimer’s disease (AD): individuals with a cancer ...

CYP2D6 poor metabolizers had ~5-fold higher payload exposure and excess grade ≥3 mucositis, neutropenia, febrile neutropenia, ...

Israeli-led researchers have identified a previously underappreciated mechanism that may explain why many prostate cancers ...

Now, after years of experimenting with common bean plants in the lab and in the agricultural fields of Oaxaca, Mexico, ...

Pfizer announces positive results from TALAPRO-3 study of Talzenna plus Xtandi in metastatic prostate cancer: New York Tuesday, June 2, 2026, 18:00 Hrs [IST] Pfizer Inc. announced ...

ASCO 2026: PSMAddition shows 177Lu-PSMA-617 boosts rPFS across mHSPC subgroups, with steady safety and insights on PSMA PET ...

May 31 (Reuters) - Johnson & Johnson's (JNJ.N) ​prostate cancer drug Erleada used with hormone-blocking therapy six months ...

Data from a late-stage trial, presented on Sunday, indicate that the treatment, administered six months before and after ...

Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis ...

Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, today announced updated clinical ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...